Provides biosensors and kits for bioprocess monitoring. Offers compliance tools and systems software for regulated industries. Now — the numbers.
This is an established company with proven profits.
No real growth.
The gap is $4.3B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 87.9× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 78% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It pays out $0.17 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales fell about 0% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The company’s market value is 88 times its annual profit. Even a small disappointment could hit the price hard.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.